MDM2 and CDK4 Immunostainings Are Useful Adjuncts in Diagnosing Well-Differentiated and Dedifferentiated Liposarcoma Subtypes: A Comparative Analysis of 559 Soft Tissue Neoplasms With Genetic Data

By M. B. N. Binh, X. Sastre‐Garau, L. Guillou, G. Pinieux, P. Terrier, R. Lagacé, A. Aurias, I. Hostein, J. Coindre. American Journal of Surgical Pathology, 2005

594 citations recorded by the source corpus.

Subfields: Cardiology and Cardiovascular Medicine, Pathology and Forensic Medicine, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/ffe7a3c2f2a30c53779c69d0dd4b685fe3d64862

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. B. Gleason
2. V. Jo
3. J. Hornick
4. C. Fletcher
5. E. Ewing

Citations in the corpus

• WHO classification of soft tissue tumours: an update based on the 2013 (4th) edition (2014, background): “antibodies against the gene products coded on 12q13-15 that are amplified (in either supernumerary ring or giant marker chromosomes) in atypical lipomatous tumour/well-differentiated liposarcoma and dedifferentiated liposarcoma.(4,5) For negative or equivocal immunohistochemical results found in cli”
• Inflammatory myofibroblastic tumours: where are we now? (2007, background): “…on a biopsy specimen, as morphologically low grade lesions are often remarkably bland, 80–82 and immunohistochemistry for MDM2, a sensitive marker of dedifferentiated liposarcoma, 83 is not helpful in this distinction, given that a significant proportion of IMTs show nuclear MDM2 expression.”